AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05283720
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV); Injection
Trial: NCT05283720
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT05283720
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV; Injection
Trial: NCT05283720
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral; Tablet
Trial: NCT05283720
Drug: CC-99282
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Capsule
Trial: NCT05283720
Drug: Pirtobrutinib
RxNorm normalized name: Pirtobrutinib
DrugBank: Pirtobrutinib (DB17472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral; Tablet
Trial: NCT05294744
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.
Trial: NCT04961788
Drug: Gemox combimed PD1 antibody
RxNorm normalized name: Hemox A
DrugBank: Aluminum chloride (DB11081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses.
Trial: NCT05583266
Drug: Pentoxifylline sustained-release tablets
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a dose of 1 tablet twice a day of Pentoxifylline sustained-release tablets
Trial: NCT05583266
Drug: Pentoxifylline sustained-release tablets placebo
RxNorm normalized name: INV-CSP2008 PENTOXIFYLLINE SA 400MG/PLACEBO
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline sustained-release tablets placebo will be administrated at the same dosage and frequency as the experimental group
Trial: NCT04836494
Drug: BBP-671
RxNorm normalized name: BBP-671
DrugBank: BBP-671 (DB18498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBP-671, oral suspension
Trial: NCT04836494
Drug: BBP-671
RxNorm normalized name: BBP-671
DrugBank: BBP-671 (DB18498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBP-671, tablet
Trial: NCT05224531
Drug: CS1 Administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CS1 delayed-release capsules will be supplied with 160 mg active pharmaceutical ingredient (sodium valproate) per capsule. Three dose levels that will be evaluated in this study; study drug will be administered as uneven, divided doses twice daily in the morning and in the evening (1/3 of the daily dose is to be administered between 7 and 9 am; 2/3 of the daily dose is to be administered between 7 and 9 pm).
Trial: NCT06152796
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti_inflammatory drug
Trial: NCT06575725
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT06047535
Drug: Naxitamab
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naxitamab + GM-CSF:~Cycles 1-5: Patients will receive naxitamab IV at 3 mg/kg/infusion on Day 1, 3 and 5 and GM-CSF sc at 5 µg/kg/day on Days -4 to 0 and at 10 µg/kg/day on Days 1-5 for 5 cycles.~Isotretinoin:~Cycles 3-8: Patients will receive isotretinoin PO at 160 mg/m2/day divided into two daily doses on Days 15-28 for 6 cycles.
Trial: NCT06372964
Drug: Lumateperone
RxNorm normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lumateperone administered orally, once daily.
Trial: NCT06627218
Drug: Prothrombin Complex Concentrate
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Factor IX Complex (Human) (DB11330)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma
Trial: NCT05119712
Drug: Terbinafine Tablets
RxNorm normalized name: Terbinafine Tablets
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg oral terbinafine or placebo daily
Trial: NCT04834531
Drug: Zhuli capsule
RxNorm normalized name: Rhuli
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This capsule is made from the exact of Phyllostachys glauca McClure or Phyllostachysnuda McClure, which has the expectorant effects. It is oral used,2 capsules for once, three times a day, for 7 days.
Trial: NCT05087069
Drug: BV100
RxNorm normalized name: Bempedoic Acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rifabutin for Infusion
Trial: NCT05524935
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab Day 1 of each 21 day (3 week) cycle
Trial: NCT05524935
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib by mouth days 1-21 of each 21 day (3 week) cycle
Trial: NCT05179317
Drug: QL1706
RxNorm normalized name: QL1706
DrugBank: QL1706 (DB17562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion
Trial: NCT05286229
Drug: ABBV-383
RxNorm normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) Infusion
Trial: NCT05513937
Drug: Nebivolol
RxNorm normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily according instructions provided by Principal Investigator.
Trial: NCT05513937
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Trial: NCT05559827
Drug: Isatuximab
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab treatment at a dose of 10 mg/kg by intravenous route. The first injection of isatuximab will be performed at randomization (month 6 +/- 2 days). A second injection may be performed at day 15 if the reticulocytes \<10 G / L, and a third at day 29 if reticulocytes \<10 G / L. Patients will be assessed on day 1, day 15, day 29, day 45, 2 months, 3 months, 6 months and 9 months after randomization.
Trial: NCT04901169
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Infusion of Angiotensin II initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Trial: NCT04901169
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion of 0.9% saline initiated if participants require norepinephrine at a rate of \> 0.05 mcg/kg/min. The infusion will be titrated no more frequently than every 10 minutes during liver transplantation as a second line vasopressor and discontinued prior to leaving the operating room when the surgery is complete.
Trial: NCT04602754
Drug: EMPAGLIFLOZIN
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 25 mg coated tablet.
Trial: NCT05216562
Drug: Exosome-MSC Intravenous injection
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs)
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of Exosome-MSC
Trial: NCT05788679
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine
Trial: NCT05029063
Drug: Rivaroxaban 10 MG
RxNorm normalized name: rivaroxaban 10 MG
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Identical comparator drug
Trial: NCT05398094
Drug: Sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.
Trial: NCT06537115
Drug: Eldecalcitol
RxNorm normalized name: Eldecalcitol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
Trial: NCT04789486
Drug: AGuIX
RxNorm normalized name: AGuIX
DrugBank: AGuIX (DB18189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected gadolinium-based nanoparticles
Trial: NCT03967548
Drug: Germinal peptide eye drops
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Germinal peptide eye drops of 0.004%
Trial: NCT05110976
Drug: AZD8630
RxNorm normalized name: AZD8630
DrugBank: AZD8630 (DB19397)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Inhaled or IV doses of AZD8630 as per the arm they are assigned.
Trial: NCT06537843
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Venetoclax, PO (tablet), 200 - 400mg, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Trial: NCT06537843
Drug: Cytarabine Injection
RxNorm normalized name: cytarabine Injection
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine, Subcutaneous injection, 10 - 100mg per square meter, once-daily, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Trial: NCT06537843
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin, PO (tablet), 850mg, three times a day, 10 days per cycle (cycle 1), 5 days per cycle (cycle 2 and subsequent cycles).
Trial: NCT04238390
Drug: Ceftolozane-Tazobactam
RxNorm normalized name: ceftolozane-tazobactam
DrugBank: Tazobactam (DB01606)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.
Trial: NCT04238390
Drug: Meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.
Trial: NCT04864444
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-PPQ will be given over the course of three consecutive days using 160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets. DHA-PPQ will be administered via age-based dosing. All three doses will be directly observed and given orally with water and without food.
Trial: NCT04864444
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primaquine will be given once with the first dose of DHA-PPQ. Primaquine will be administered in an aqueous solution according to age-based dosing guidelines.
Trial: NCT05448183
Drug: Toripalimab, Gemcitabine,Oxaliplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Toripalimab, 240mg, IV infusion, every 3 weeks (q3w), combined withTACE (Gemcitabine 1000mg/m2 , Oxaliplatin 135mg/m2) in a cycle of 3 weeks(q3w).
Trial: NCT05577442
Drug: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (8-6mg/3weekly)，Pyrotinib（320mg/day）Dalpiciclib（125mg/day，With three weeks separated by one week）
Trial: NCT06364098
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 microgram of misoprostol given either sublingually or intrauterine during CS after placental removal together with IV oxytocin infusion
Trial: NCT01582438
Drug: Access program - sildenafil citrate, Viagra, Revatio
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The recommended dose is 20 mg TID for subjects with body weight \> 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
Trial: NCT06626984
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pre-treatment with 600mg Imatinib administered 1 hour prior to intravenous LPS.
Trial: NCT06626984
Drug: Compound sodium lactate solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total of 30 ml/kg administered 90 minutes following intravenous LPS. 30mls/kg (maximum volume of 2500mls) administered in two divided doses (15mls/kg) intravenously. Each bolus will be administered at a fixed rate of 999mls/hr.
Trial: NCT00000666
Drug: Pyrimethamine
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05633862
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT05332483
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate, 160 mg daily (two 40mg tablets twice a day), for a minimum of 18 days.
Trial: NCT04847661
Drug: Mefloquine as a prophylaxis against SARS-Cov-2 infection in household contacts of COVID 19 confirmed cases
RxNorm normalized name: SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine hydrochloride will be given in a dose of 1100-1650 mg, according to body weight (BW), splitted into two to three doses.
Trial: NCT05269394
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT06095765
Drug: Colchicine 0.5 MG Oral Tablet
RxNorm normalized name: colchicine 0.5 mg oral tablet
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral intake of 0.5 mg colchicine once daily
Trial: NCT04496349
Drug: APG-115
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QOD, 2 weeks on, 1 week off, in repeated 21-day cycles
Trial: NCT04923126
Drug: Mirdametinib
RxNorm normalized name: Mirdametinib
DrugBank: Mirdametinib (DB07101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
Trial: NCT04496349
Drug: APG-2575
RxNorm normalized name: APGA
DrugBank: Aminopterin (DB08878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-2575 given orally each day in cycle, in repeated 21-day cycles
Trial: NCT05231603
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg/day-maximum dose is 24 mg.
Trial: NCT03315832
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
Trial: NCT05838391
Drug: Mitomycin-C
RxNorm normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As part of the subjects' treatment, 10 mg/meters squared of Mitomycin C will be administered intravenously (IV-into the vein) on Day 1 and Day 29.
Trial: NCT05838391
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As part of the subjects' treatment, 1g/meters squared/day for 4 days of 5-Fluorouracil will be administered by continuous infusion on Days 1-4 (for 96 hours) and Days 29-32 (for 96 hours). 5-Fluorouracil or capecitabine will be administered per the physician's discretion.
Trial: NCT01207622
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002169
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06555458
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient group to be given dexmedetomidine
Trial: NCT06555458
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient group to be given salin
Trial: NCT05491187
Drug: 0.5% bupivacaine heavy
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 0.5% bupivacaine heavy at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
Trial: NCT05491187
Drug: 0.5% bupivacaine heavy with fentanyl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 0.5% bupivacaine heavy with fentanyl at L3-L4 intervertebral space using Quincke's spinal needle in sitting position, single administration for each patient
Trial: NCT04702646
Drug: Bowel preparation before colonoscopy
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one day liquid diet will be administered to every patient included in the study and: split-dose bowel preparation with 4 Liters of Polyethylene glycol solution, 2 Liters of PEG-Ascorbic acid or 2 Liters Picosulfate.
Trial: NCT05638360
Drug: Ru Yi Jin Huang Powder
RxNorm normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patch contains 13g Ru Yi Jin Huang Powder and 10c.c. water.
Trial: NCT04613960
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset
Trial: NCT06218524
Drug: Haloperidol Tablets
RxNorm normalized name: Haloperidol Tablets
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol tablet 6mg, Oral, Triple/Day
Trial: NCT06218524
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide, 150mg/kg, Oral, Once/Day, 5/28 days
Trial: NCT06698250
Drug: Zanzalintinib
RxNorm normalized name: Zanzalintinib
DrugBank: Zanzalintinib (DB17525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Next generation tyrosine kinase inhibitor (TKI) with the target inhibition proﬁle identical to cabozantinib but with a superior pharmacokinetic proﬁle.
Trial: NCT06698250
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)
Trial: NCT06698250
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells